methyl 4-fluoro-2-methoxy-5-nitrobenzoate | 151793-17-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 4-fluoro-2-methoxy-5-nitrobenzoate
• CAS: 151793-17-8
• 化学式: C₉H₈FNO₅
• 分子量: 229.165
• InChiKey: LHAVJVZNGLTPCY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  81.4
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  methyl 4-fluoro-2-methoxy-5-nitrobenzoate 在 Ni-Raney sodium hydroxide 、 氢气 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 3.0h， 生成 5-氨基-N-[2-[环丙基(甲基)氨基]乙基]-4-氟-2-甲氧基苯甲酰胺
  参考文献：
  名称：

  Synthesis and preliminary data on new selective and potent gastric prokinetic substituted benzamides

  摘要：

  A series of amino-halogen-N-[2-aminoethyl] benzamides was synthesized and evaluated for enhancing gastric emptying. Compared to metoclopramide, domperidone and bromopride, a number of compounds were shown to be more active in enhancing gastric motility (rat stomach emptying), devoid of dopaminergic D2-receptor antagonism (rat apomorphine test) and to be less toxic.

  DOI：

  10.1016/0223-5234(93)90129-3
• 作为产物：
  描述：

  4-氟-2-甲氧基苯甲酸甲酯 在 硫酸 、 potassium nitrate 作用下， 反应 3.0h， 以8.24 g的产率得到methyl 4-fluoro-2-methoxy-5-nitrobenzoate
  参考文献：
  名称：

  [EN] 9H-PYRIMIDO [4,5-B] INDOLES AS BET BROMODOMAIN INHIBITORS
  [FR] 9H-PYRIMIDO[4,5-B]INDOLES UTILISÉS COMME INHIBITEURS DES BROMODOMAINES BET

  摘要：

  本公开提供了代表为公式I的取代9H-嘧啶并[4,5-b]吲哚和5H-吡啶并[4,3-b]吲哚及相关类似物的药物可接受的盐、水合物和溶剂化合物，其中R1a、W、B1、B2、G、X1、Y1、Y2和Y3如规范中所定义。本公开还涉及使用公式I的化合物来治疗对BET溴结构域抑制具有响应的疾病或疾病，如癌症。本公开还涉及将公式I的化合物用作合成中间体。

  公开号：

  WO2016138332A1

文献信息

• [EN] HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS<br/>[FR] MODULATEURS ALLOSTÉRIQUES DES PROTÉINES DU NOYAU DE L'HÉPATITE B
  申请人：UNIV INDIANA RES & TECH CORP

  公开号：WO2015138895A1

  公开（公告）日：2015-09-17

  ABSTRACT The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

  摘要 本公开提供了部分具有对乙型肝炎病毒Cp具有变构效应的化合物。本文还提供了治疗病毒感染（如乙型肝炎）的方法，包括向需要的患者施用所述化合物。
• TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE
  申请人：BAHADOOR Adilah

  公开号：US20110274655A1

  公开（公告）日：2011-11-10

  Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables R A , R B and R C are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.

  本文提供了式(I)的四唑酮FASN抑制剂或其药用可接受形式；其中变量RA、RB和RC在此处定义。本文还提供了所述化合物的药物组合物以及它们用于治疗各种疾病的方法，如过度增殖性疾病、炎症性疾病、与肥胖有关的疾病和微生物感染。
• [EN] N-MENTHYLBENZIMIDAZOLES AS MIDH1 INHIBITORS<br/>[FR] N-MENTHYLBENZIMIDAZOLES À TITRE D'INHIBITEURS DE MIDH1
  申请人：BAYER PHARMA AG

  公开号：WO2016198322A1

  公开（公告）日：2016-12-15

  The present invention relates to benzimidazol-2-amines of general formula (I), in which R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.

  本发明涉及一般式(I)的苯并咪唑-2-胺化合物，其中R1、R2、R3、R4、R5、R6、R7和R8如本文所定义，以及制备所述化合物的方法，用于制备所述化合物的有用中间体化合物，包含所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是肿瘤，作为唯一药剂或与其他活性成分结合使用。
• QUINOXALINE COMPOUND
  申请人：Kaizawa Hiroyuki

  公开号：US20110319385A1

  公开（公告）日：2011-12-29

  [Problem] Provided is a compound which has a PDE9-inhibiting action and is useful as an active ingredient for an agent for treating and/or preventing storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like. [Means for Solution] The present inventors have investigated a compound which has a PDE9-inhibiting action and is useful as an active ingredient for an agent for treating and/or preventing storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like, and thus, have found that an imidazoquinoxaline compound or a triazoloquinoxaline compound has a PDE9-inhibiting action, thereby completing the present invention. The imidazoquinoxaline compound or the triazoloquinoxaline compound of the present invention has a PDE9-inhibiting action and can be used as an agent for preventing and/or treating storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like.

  提供一种具有PDE9抑制作用的化合物，可用作治疗和/或预防储存功能障碍、排尿功能障碍、膀胱/尿道疾病等药剂的活性成分。现有发明人研究了一种具有PDE9抑制作用的化合物，可用作治疗和/或预防储存功能障碍、排尿功能障碍、膀胱/尿道疾病等药剂的活性成分，因此，发现咪唑喹喔啉化合物或三唑喹喔啉化合物具有PDE9抑制作用，从而完成了本发明。本发明的咪唑喹喔啉化合物或三唑喹喔啉化合物具有PDE9抑制作用，可用作预防和/或治疗储存功能障碍、排尿功能障碍、膀胱/尿道疾病等药剂。
• [EN] 9H-PYRIMIDO [4,5-B] INDOLES AS BET BROMODOMAIN INHIBITORS<br/>[FR] 9H-PYRIMIDO[4,5-B]INDOLES UTILISÉS COMME INHIBITEURS DES BROMODOMAINES BET
  申请人：UNIV MICHIGAN REGENTS

  公开号：WO2016138332A1

  公开（公告）日：2016-09-01

  The present disclosure provides substituted 9H-pyrimido [4,5-b] indoles and 5H-pyrido [4,3-b] indoles and related analogs represented by Formula I and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R 1a, W, B 1, B2, G, X 1, Y1, Y2, and Y 3 are as defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a condition or disorder responsive to inhibition of BET bromodomains such as cancer. The present disclosure is also directed to the use of compound of Formula I as synthetic intermediates.

  本公开提供了代表为公式I的取代9H-嘧啶并[4,5-b]吲哚和5H-吡啶并[4,3-b]吲哚及相关类似物的药物可接受的盐、水合物和溶剂化合物，其中R1a、W、B1、B2、G、X1、Y1、Y2和Y3如规范中所定义。本公开还涉及使用公式I的化合物来治疗对BET溴结构域抑制具有响应的疾病或疾病，如癌症。本公开还涉及将公式I的化合物用作合成中间体。